{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:19:09Z","timestamp":1789611549161,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304639"],"award-info":[{"award-number":["82304639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008304"],"award-info":[{"award-number":["2020YFC2008304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Voriconazole is recommended as first-line therapy for invasive fungal infections but exhibits substantial pharmacokinetic (PK) variability and hepatotoxicity. Although CYP2C19 polymorphisms partially explain this variability, evidence regarding additional genetic determinants remains inconsistent. Studies integrating genetic and clinical factors for voriconazole PK and hepatotoxicity are limited.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the association between 10 genetic variants and voriconazole trough concentrations in CYP2C19 normal (NM) and intermediate (IM) metabolizers and to identify predictors of PK variability and hepatotoxicity.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This observational study included 114 adult Chinese patients receiving voriconazole between July 2022 and May 2023. Associations between genetic variants and voriconazole trough concentrations were assessed within CYP2C19 NMs and IMs. Generalized linear models (GLMs) identified predictors of PK variability, and binary logistic regression assessed hepatotoxicity risk.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Voriconazole trough concentrations varied over 40-fold (0.2\u20139\u2005\u03bcg\/mL). Nominal associations were observed for CYP3A4 (rs4646437) and NR1I2 (rs7643645, rs3814055) in NMs and for SLCO1B3 (rs4149117), SLCO2B1 (rs3781727) and NR1I2 (rs3814055) in IMs, but none remained significant after Bonferroni correction. GLM analysis identified SLCO1B3 (rs4149117), NR1I2 (rs3814055), albumin, C-reactive protein (CRP) and daily dose as predictors of PK variability. Hepatotoxicity occurred in 27.2% of patients and was associated with higher trough concentrations, whereas the NR1I2 (rs7643645) GG genotype and higher baseline platelet count were associated with reduced risk.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Marked interindividual variability in voriconazole exposure persists among CYP2C19 NMs and IMs. Integrating therapeutic drug monitoring (TDM) with genetic and clinical factors may optimize dosing and reduce hepatotoxicity risk. Larger multicentre studies are still needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkag065","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:41:54Z","timestamp":1770986514000},"source":"Crossref","is-referenced-by-count":1,"title":["Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-4036","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuya","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiming","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Qilu Hospital of Shandong University , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai ,","place":["China"]},{"name":"Department of Pharmacy, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026030201261817300_dkag065-B1","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026030201261817300_dkag065-B2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","article-title":"Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients","volume":"67","author":"Maschmeyer","year":"2007","journal-title":"Drugs"},{"key":"2026030201261817300_dkag065-B3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026030201261817300_dkag065-B4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2026030201261817300_dkag065-B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030201261817300_dkag065-B6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2026030201261817300_dkag065-B7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026030201261817300_dkag065-B8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00134-024-07341-7","article-title":"Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM","volume":"50","author":"Bassetti","year":"2024","journal-title":"Intensive Care Med"},{"key":"2026030201261817300_dkag065-B9","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030201261817300_dkag065-B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026030201261817300_dkag065-B11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/17425255.2017.1391213","article-title":"Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy","volume":"13","author":"Amsden","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026030201261817300_dkag065-B12","doi-asserted-by":"publisher","first-page":"e00665","DOI":"10.1002\/prp2.665","article-title":"Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections","volume":"8","author":"Chuwongwattana","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"2026030201261817300_dkag065-B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41397-020-0166-1","article-title":"Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers","volume":"20","author":"Lee","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"2026030201261817300_dkag065-B14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0000000000000464","article-title":"Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients","volume":"32","author":"Fan","year":"2022","journal-title":"Pharmacogenet Genomics"},{"key":"2026030201261817300_dkag065-B15","doi-asserted-by":"publisher","first-page":"e00935","DOI":"10.1002\/prp2.935","article-title":"Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole","volume":"10","author":"Aiuchi","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"2026030201261817300_dkag065-B16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00228-020-02831-1","article-title":"Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms","volume":"76","author":"Zeng","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026030201261817300_dkag065-B17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/pgs-2017-0173","article-title":"Pharmacogenetic of voriconazole antifungal agent in pediatric patients","volume":"19","author":"Allegra","year":"2018","journal-title":"Pharmacogenomics"},{"key":"2026030201261817300_dkag065-B18","doi-asserted-by":"publisher","first-page":"1368274","DOI":"10.3389\/fphar.2024.1368274","article-title":"Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026030201261817300_dkag065-B19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan","volume":"63","author":"Hamada","year":"2020","journal-title":"Mycoses"},{"key":"2026030201261817300_dkag065-B20","doi-asserted-by":"publisher","first-page":"106692","DOI":"10.1016\/j.ijantimicag.2022.106692","article-title":"Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026030201261817300_dkag065-B21","author":"U.S. Department of Health and Human Services"},{"key":"2026030201261817300_dkag065-B22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jchromb.2015.02.011","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS\/MS) assay to quantify serum voriconazole","volume":"986\u2013987","author":"Mak","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026030201261817300_dkag065-B23","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026030201261817300_dkag065-B24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026030201261817300_dkag065-B25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","article-title":"Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections","volume":"27","author":"Hamadeh","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"2026030201261817300_dkag065-B26","doi-asserted-by":"publisher","first-page":"1439586","DOI":"10.3389\/fphar.2024.1439586","article-title":"Voriconazole: a review of adjustment programs guided by therapeutic drug monitoring","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026030201261817300_dkag065-B27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.2174\/1389200219666171227200547","article-title":"Interpersonal factors in the pharmacokinetics and pharmacodynamics of voriconazole: are CYP2C19 genotypes enough for us to make a clinical decision?","volume":"19","author":"Zhong","year":"2018","journal-title":"Curr Drug Metab"},{"key":"2026030201261817300_dkag065-B28","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3390\/jcm10102089","article-title":"Combined impact of inflammation and pharmacogenomic variants on voriconazole trough concentrations: a meta-analysis of individual data","volume":"10","author":"Bolcato","year":"2021","journal-title":"J Clin Med"},{"key":"2026030201261817300_dkag065-B29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr Rev"},{"key":"2026030201261817300_dkag065-B30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.bcp.2012.01.030","article-title":"Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters","volume":"83","author":"Chen","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2026030201261817300_dkag065-B31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijantimicag.2019.06.026","article-title":"Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population","volume":"54","author":"Dapia","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026030201261817300_dkag065-B32","doi-asserted-by":"publisher","first-page":"100023","DOI":"10.1016\/j.pharmr.2024.100023","article-title":"Organic anion transporting polypeptides: pharmacology, toxicology, structure, and transport mechanisms","volume":"77","author":"Hagenbuch","year":"2025","journal-title":"Pharmacol Rev"},{"key":"2026030201261817300_dkag065-B33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.pharmthera.2018.12.009","article-title":"Organic anion transporting polypeptide 2B1\u2014more than a glass-full of drug interactions","volume":"196","author":"McFeely","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2026030201261817300_dkag065-B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40780-016-0044-9","article-title":"A retrospective analysis of patient-specific factors on voriconazole clearance","volume":"2","author":"Dote","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"2026030201261817300_dkag065-B35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/antibiotics9090574","article-title":"Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in Thai patients with hematologic diseases","volume":"9","author":"Khan-Asa","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2026030201261817300_dkag065-B36","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1128\/AAC.04789-14","article-title":"Influence of inflammation on voriconazole metabolism","volume":"59","author":"Encalada Ventura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030201261817300_dkag065-B37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.pharmtox.46.120604.141059","article-title":"Regulation of drug-metabolizing enzymes and transporters in inflammation","volume":"46","author":"Aitken","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026030201261817300_dkag065-B38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026030201261817300_dkag065-B39","doi-asserted-by":"publisher","first-page":"106750","DOI":"10.1016\/j.ijantimicag.2023.106750","article-title":"Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model","volume":"61","author":"van den Born","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026030201261817300_dkag065-B40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2026030201261817300_dkag065-B41","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026030201261817300_dkag065-B42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/bcpt.13208","article-title":"Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: a population pharmacokinetic approach","volume":"125","author":"Tang","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026030201261817300_dkag065-B43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2021.01.029","article-title":"Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry","volume":"75","author":"Stephens","year":"2021","journal-title":"J Hepatol"},{"key":"2026030201261817300_dkag065-B44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag065\/67194542\/dkag065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag065\/67194542\/dkag065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:26:23Z","timestamp":1772432783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag065\/8503060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag065","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag065"}}